• Peyman Adibi, Pejman Mollakhalili, Zahra Fallah, DaryaniNasser EbrahimiNE, Hossein Ajdarkosh, Hossein Khedmat, Faramarz Derakhshan, Ashraf Karbassi, Mahshid Ashkzari, and Hamid Tavakkoli.
• Associate Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
• J Res Med Sci. 2011 Jan 1; 16 (1): 6156-15.

BackgroundUlcerative colitis (UC) is a disabling disease with increasing incidence in Iran. In spite of combined medical therapy, some patients eventually undergo total colectomy. Infliximab has proved itself as a rescue therapy and even as an early aggressive therapy for severe extensive UC. Meantime, there are concerns about its complications. The aim of this study was to evaluate the efficacy of infliximab in Iranian refractory UC patients.MethodsThis multi centric case-series study included 29 UC patients receiving two to three of the drugs prednisolone, AZT/6MP and 5ASA but yet having flare-ups. At first, the extent of colon involvement was determined by colonoscopy; then the drug was administered at baseline, 2nd week and 6th week and colonoscopy repeated afterwards. Clinical and laboratory data were also recorded.ResultsIn first endoscopy 18 patients (62%) out of 29 suffered from pancolitis and none had normal results. In second examination (done on 19 patients), one was normal and only 8 of 18 (27.6%) had pancolitis. Considering missing cases, at least in 33.3% of patients the drug has reduced the extreme extent of colon involvement. Also a wilcoxon signed ranks test revealed significant reduction of the disease extension after this treatment (p = 0.008). There were only one leucopenic and one hypotensive reactions in short term. The drug showed effectiveness in the term of disease modifying, too.ConclusionsThese data show the usefulness of the drug in refractory UC. Longer follow ups and controlled trials are needed.

4 keywords...

hide…